Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martti Nurmi

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|May 3, 2011
[Treatment of benign prostatic hyperplasia]Martti Nurmi
BJU International|August 2, 2008
Risk factors for mortality and morbidity related to radical cystectomyPeter J Boström, Jyrki Kössi, Matti Laato, et al.
Duodecim; Laaketieteellinen Aikakauskirja|June 26, 2012
[Update on current care guidelines: benign prostatic hyperplasia]Teuvo Tammela, Martti Nurmi, Anssi Pétas, et al.
Urology|July 18, 2006
Free and total human glandular kallikrein 2 in patients with prostate cancerVille Väisänen, Kim Pettersson, Kalle Alanen, et al.
Analytical Chemistry|November 16, 2006
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragmentsVille Väisänen, Mari T Peltola, Hans Lilja, et al.
Scandinavian Journal of Urology and Nephrology|November 20, 2009
Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centrePeter J Boström, Tuomas Mirtti, Jyrki Kössi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Associations between serum testosterone fall and cognitive function in prostate cancer patientsEeva K Salminen, Raija I Portin, Aki Koskinen, et al.
Journal of Immunological Methods|May 11, 2011
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆)Mari T Peltola, Pauliina Niemelä, Kalle Alanen, et al.
Clinical Chemistry|July 13, 2004
Development of sensitive immunoassays for free and total human glandular kallikrein 2Ville Väisänen, Susann Eriksson, Kaisa K Ivaska, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2003
Kinetics of [(11)C]choline uptake in prostate cancer: a PET studyEija Sutinen, Martti Nurmi, Anne Roivainen, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Duodecim; Laaketieteellinen Aikakauskirja|May 3, 2011
[Treatment of benign prostatic hyperplasia]Martti Nurmi
BJU International|August 2, 2008
Risk factors for mortality and morbidity related to radical cystectomyPeter J Boström, Jyrki Kössi, Matti Laato, et al.
Duodecim; Laaketieteellinen Aikakauskirja|June 26, 2012
[Update on current care guidelines: benign prostatic hyperplasia]Teuvo Tammela, Martti Nurmi, Anssi Pétas, et al.
Urology|July 18, 2006
Free and total human glandular kallikrein 2 in patients with prostate cancerVille Väisänen, Kim Pettersson, Kalle Alanen, et al.
Analytical Chemistry|November 16, 2006
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragmentsVille Väisänen, Mari T Peltola, Hans Lilja, et al.
Scandinavian Journal of Urology and Nephrology|November 20, 2009
Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centrePeter J Boström, Tuomas Mirtti, Jyrki Kössi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Associations between serum testosterone fall and cognitive function in prostate cancer patientsEeva K Salminen, Raija I Portin, Aki Koskinen, et al.
Journal of Immunological Methods|May 11, 2011
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆)Mari T Peltola, Pauliina Niemelä, Kalle Alanen, et al.
Clinical Chemistry|July 13, 2004
Development of sensitive immunoassays for free and total human glandular kallikrein 2Ville Väisänen, Susann Eriksson, Kaisa K Ivaska, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2003
Kinetics of [(11)C]choline uptake in prostate cancer: a PET studyEija Sutinen, Martti Nurmi, Anne Roivainen, et al.
Pageof 3